ABC transporters at the blood–brain barrier

Topics in Medicinal Chemistry

Volumn 10, Issue , 2014, Pages 49-70

  Miller, David S ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

BCRP; Blood brain barrier; Brain capillary endothelium; Disease; Drug delivery; MRP; P glycoprotein; Regulation

Indexed keywords

ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; ESTROGEN; MULTIDRUG RESISTANCE PROTEIN; SPHINGOLIPID; VASCULOTROPIN; XENOBIOTIC AGENT;

ARTICLE; BLOOD BRAIN BARRIER; CAPILLARY ENDOTHELIUM; CENTRAL NERVOUS SYSTEM; DRUG DESIGN; DRUG TARGETING; HUMAN; MICROARRAY ANALYSIS; NONHUMAN; PHARMACODYNAMICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; SPINAL CORD; TISSUE DISTRIBUTION; TOXICOKINETICS;

EID: 84921646765     PISSN: 18622461     EISSN: 1862247X     Source Type: Book Series    
DOI: 10.1007/7355_2013_31     Document Type: Article

References (79)

1. Zlokovic BV (2008) The blood–brain barrier in health and chronic neurodegenerative disorders. Neuron 57(2):178–201. doi:10.1016/j.neuron.2008.01.003
2. Zlokovic BV (2011) Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nat Rev Neurosci 12(12):723–738. doi:10.1038/nrn3114
3. Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455(1):152–162
4. Gottesman MM, Ling V (2006) The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett 580(4):998–1009. doi:10.1016/j.febslet. 2005.12.060
5. Bodo A, Bakos E, Szeri F, Varadi A, Sarkadi B (2003) The role of multidrug transporters in drug availability, metabolism and toxicity. Toxicol Lett 140–141:133–143
6. Konig J, Muller F, Fromm MF (2013) Transporters and drug-drug interactions: important determinants of drug disposition and effects. Pharmacol Rev 65(3):944–966. doi:10.1124/pr. 113.007518
7. Stanley LA, Horsburgh BC, Ross J, Scheer N, Wolf CR (2009) Drug transporters: gatekeepers controlling access of xenobiotics to the cellular interior. Drug Metab Rev 41 (1):27–65. doi:10.1080/03602530802605040
8. Moitra K, Dean M (2011) Evolution of ABC transporters by gene duplication and their role in human disease. Biol Chem 392(1–2):29–37. doi:10.1515/BC.2011.006
9. Hartz AM, Bauer B (2011) ABC transporters in the CNS – an inventory. Curr Pharm Biotechnol 12(4):656–673
10. Dallas S, Miller DS, Bendayan R (2006) Multidrug resistance-associated proteins: expression and function in the central nervous system. Pharmacol Rev 58(2):140–161. doi:10.1124/pr.58.2.3
11. Bendayan R, Lee G, Bendayan M (2002) Functional expression and localization of P-glycoprotein at the blood brain barrier. Microsc Res Tech 57(5):365–380. doi:10.1002/jemt. 10090
12. Hawkins BT, Rigor RR, Miller DS (2010) Rapid loss of blood–brain barrier P-glycoprotein activity through transporter internalization demonstrated using a novel in situ proteolysis protection assay. J Cereb Blood Flow Metab 30(9):1593–1597. doi:10.1038/jcbfm.2010.117
13. Kis O, Robillard K, Chan GN, Bendayan R (2010) The complexities of antiretroviral drugdrug interactions: role of ABC and SLC transporters. Trends Pharmacol Sci 31(1):22–35. doi:10.1016/j.tips.2009.10.001
14. Ronaldson PT, Persidsky Y, Bendayan R (2008) Regulation of ABC membrane transporters in glial cells: relevance to the pharmacotherapy of brain HIV-1 infection. Glia 56(16):1711–1735. doi:10.1002/glia.20725
15. Aronica E, Sisodiya SM, Gorter JA (2012) Cerebral expression of drug transporters in epilepsy. Adv Drug Deliv Rev 64(10):919–929. doi:10.1016/j.addr.2011.11.008
16. Kannan P, John C, Zoghbi SS, Halldin C, Gottesman MM, Innis RB, Hall MD (2009) Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin Pharmacol Ther 86(4):368–377. doi:10.1038/clpt.2009.138
17. Miller DS (2010) Regulation of P-glycoprotein and other ABC drug transporters at the blood–brain barrier. Trends Pharmacol Sci 31(6):246–254. doi:10.1016/j.tips.2010.03.003
18. Miller DS, Cannon RE (2013) Signaling Pathways that Regulate Basal ABC Transporter Activity at the Blood–brain Barrier. Curr Pharm Des
19. Kohle C, Bock KW (2009) Coordinate regulation of human drug-metabolizing enzymes, and conjugate transporters by the Ah receptor, pregnane X receptor and constitutive androstane receptor. Biochem Pharmacol 77(4):689–699
20. Pascussi JM, Gerbal-Chaloin S, Duret C, Daujat-Chavanieu M, Vilarem MJ, Maurel P (2008) The tangle of nuclear receptors that controls xenobiotic metabolism and transport: crosstalk and consequences. Annu Rev Pharmacol Toxicol 48:1–32
21. White SS, Birnbaum LS (2009) An overview of the effects of dioxins and dioxin-like compounds on vertebrates, as documented in human and ecological epidemiology. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 27(4):197–211. doi:10.1080/10590500903310047
22. Bauer B, Hartz AM, Fricker G, Miller DS (2004) Pregnane X receptor up-regulation of P-glycoprotein expression and transport function at the blood–brain barrier. Mol Pharmacol 66(3):413–419. doi:10.1124/mol.66.3
23. Dauchy S, Dutheil F, Weaver RJ, Chassoux F, Daumas-Duport C, Couraud PO, Scherrmann JM, De Waziers I, Decleves X (2008) ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood–brain barrier. J Neurochem 107 (6):1518–1528
24. Nannelli A, Rossignolo F, Tolando R, Rossato P, Pellegatti M, Longo V, Giovanni Gervasi P (2010) Expression and distribution of CYP3A genes, CYP2B22, and MDR1, MRP1, MRP2, LRP efflux transporters in brain of control and rifampicin-treated pigs. Mol Cell Biochem 337 (1–2):133–143
25. Ott M, Fricker G, Bauer B (2009) Pregnane X receptor (PXR) regulates P-glycoprotein at the blood–brain barrier: functional similarities between pig and human PXR. J Pharmacol Exp Ther 329(1):141–149
26. Bauer B, Hartz AM, Lucking JR, Yang X, Pollack GM, Miller DS (2008) Coordinated nuclear receptor regulation of the efflux transporter, Mrp2, and the phase-II metabolizing enzyme, GSTpi, at the blood–brain barrier. J Cereb Blood Flow Metab 28(6):1222–1234. doi:10.1038/jcbfm.2008.16
27. Wang X, Hawkins BT, Miller DS (2011) Activating PKC-beta1 at the blood–brain barrier reverses induction of P-glycoprotein activity by dioxin and restores drug delivery to the CNS. J Cereb Blood Flow Metab 31(6):1371–1375. doi:10.1038/jcbfm.2011.44
28. Wang X, Sykes DB, Miller DS (2010) Constitutive androstane receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood–brain barrier. Mol Pharmacol 78(3):376–383. doi:10.1124/mol.110.063685
29. Bauer B, Yang X, Hartz AM, Olson ER, Zhao R, Kalvass JC, Pollack GM, Miller DS (2006) In vivo activation of human pregnane X receptor tightens the blood–brain barrier to methadone through P-glycoprotein up-regulation. Mol Pharmacol 70(4):1212–1219. doi:10.1124/mol.106.023796
30. Wang X, Hawkins BT, Miller DS (2011) Aryl hydrocarbon receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood–brain barrier. FASEB J 25(2):644–652. doi:10.1096/fj.10-169227
31. ElAli A, Hermann DM (2012) Liver X receptor activation enhances blood–brain barrier integrity in the ischemic brain and increases the abundance of ATP-binding cassette transporters ABCB1 and ABCC1 on brain capillary cells. Brain Pathol 22(2):175–187. doi:10.1111/j.1750-3639.2011.00517.x
32. Chow EC, Durk MR, Cummins CL, Pang KS (2011) 1Alpha,25-dihydroxyvitamin D3 up-regulates P-glycoprotein via the vitamin D receptor and not farnesoid X receptor in both fxr(-/-) and fxr(+/+) mice and increased renal and brain efflux of digoxin in mice in vivo. J Pharmacol Exp Ther 337(3):846–859. doi:10.1124/jpet.111.179101
33. Durk MR, Chan GN, Campos CR, Peart JC, Chow EC, Lee E, Cannon RE, Bendayan R, Miller DS, Pang KS (2012) 1alpha,25-Dihydroxyvitamin D3-liganded vitamin D receptor increases expression and transport activity of P-glycoprotein in isolated rat brain capillaries and human and rat brain microvessel endothelial cells. J Neurochem 123(6):944–953. doi:10.1111/jnc.12041
34. Narang VS, Fraga C, Kumar N, Shen J, Throm S, Stewart CF, Waters CM (2008) Dexamethasone increases expression and activity ofmultidrug resistance transporters at the rat blood–brain barrier. Am J Physiol Cell Physiol 295(2):C440–C450. doi:10.1152/ajpcell.00491.2007
35. Vogelgesang S, Cascorbi I, Schroeder E, Pahnke J, Kroemer HK, Siegmund W, Kunert-Keil C, Walker LC, Warzok RW (2002) Deposition of Alzheimer’s beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 12(7):535–541
36. Vogelgesang S, Glatzel M, Walker LC, Kroemer HK, Aguzzi A, Warzok RW (2006) Cerebrovascular P-glycoprotein expression is decreased in Creutzfeldt-Jakob disease. Acta Neuropathol 111(5):436–443
37. Vautier S, Fernandez C (2009) ABCB1: the role in Parkinson’s disease and pharmacokinetics of antiparkinsonian drugs. Expert Opin Drug Metab Toxicol 5(11):1349–1358
38. Langford D, Grigorian A, Hurford R, Adame A, Ellis RJ, Hansen L, Masliah E (2004) Altered P-glycoprotein expression in AIDS patients with HIV encephalitis. J Neuropathol Exp Neurol 63(10):1038–1047
39. Bauer M, Karch R, Neumann F, Abrahim A, Wagner CC, Kletter K, Muller M, Zeitlinger M, Langer O (2009) Age dependency of cerebral P-gp function measured with (R)-[11C] verapamil and PET. Eur J Clin Pharmacol 65(9):941–946
40. Loscher W, Potschka H (2005) Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 6(8):591–602
41. ElAli A, Hermann DM (2010) Apolipoprotein E controls ATP-binding cassette transporters in the ischemic brain. Sci Signal 3(142):ra72. doi:10.1126/scisignal.2001213
42. Bauer B, Hartz AM, Miller DS (2007) Tumor necrosis factor alpha and endothelin-1 increase P-glycoprotein expression and transport activity at the blood–brain barrier. Mol Pharmacol 71(3):667–675. doi:10.1124/mol.106.029512
43. Hartz AM, Bauer B, Block ML, Hong JS, Miller DS (2008) Diesel exhaust particles induce oxidative stress, proinflammatory signaling, and P-glycoprotein up-regulation at the blood–brain barrier. FASEB J 22(8):2723–2733. doi:10.1096/fj.08-106997
44. Bauer B, Hartz AM, Pekcec A, Toellner K, Miller DS, Potschka H (2008) Seizure-induced up-regulation of P-glycoprotein at the blood–brain barrier through glutamate and cyclooxygenase-2 signaling. Mol Pharmacol 73(5):1444–1453. doi:10.1124/mol.107.041210
45. Hartz AM, Notenboom S, Bauer B (2009) Signaling to P-glycoprotein-A new therapeutic target to treat drug-resistant epilepsy? Drug News Perspect 22(7):393–397
46. Zibell G, Unkruer B, Pekcec A, Hartz AM, Bauer B, Miller DS, Potschka H (2009) Prevention of seizure-induced up-regulation of endothelial P-glycoprotein by COX-2 inhibition. Neuropharmacology 56(5):849–855. doi:10.1016/j.neuropharm.2009.01.009
47. Kuhnke D, Jedlitschky G, Grube M, Krohn M, Jucker M, Mosyagin I, Cascorbi I, Walker LC, Kroemer HK, Warzok RW, Vogelgesang S (2007) MDR1-P-Glycoprotein (ABCB1) mediates transport of Alzheimer’s amyloid-beta peptides–implications for the mechanisms of Abeta clearance at the blood–brain barrier. Brain Pathol 17(4):347–353
48. Tai LM, Loughlin AJ, Male DK, Romero IA (2009) P-glycoprotein and breast cancer resistance protein restrict apical-to-basolateral permeability of human brain endothelium to amyloid-beta. J Cereb Blood Flow Metab 29(6):1079–1083
49. Xiong H, Callaghan D, Jones A, Bai J, Rasquinha I, Smith C, Pei K, Walker D, Lue LF, Stanimirovic D, Zhang W (2009) ABCG2 is upregulated in Alzheimer’s brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood–brain barrier for Abeta(1–40) peptides. J Neurosci 29(17):5463–5475
50. Hartz AM, Miller DS, Bauer B (2010) Restoring blood–brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer’s disease. Mol Pharmacol 77(5):715–723. doi:10.1124/mol.109.061754
51. Spudich A, Kilic E, Xing H, Kilic U, Rentsch KM, Wunderli-Allenspach H, Bassetti CL, Hermann DM (2006) Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischemia. Nat Neurosci 9(4):487–488. doi:10.1038/nn1676
52. Agarwal S, Hartz AM, Elmquist WF, Bauer B (2011) Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up. Curr Pharm Des 17(26):2793–2802
53. Polli JW, Olson KL, Chism JP, John-Williams LS, Yeager RL, Woodard SM, Otto V, Castellino S, Demby VE (2009) An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl) ethy l]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016). Drug Metab Dispos 37 (2):439–442
54. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhanel M, Spruss T, Bernhardt G, Graeff C, Farber L, Gschaidmeier H, Buschauer A, Fricker G (2002) Transport of paclitaxel (Taxol) across the blood–brain barrier in vitro and in vivo. J Clin Invest 110(9):1309–1318. doi:10.1172/ JCI15451
55. Ferry DR, Traunecker H, Kerr DJ (1996) Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer 32A(6):1070–1081
56. Kalvass JC, Polli JW, Bourdet DL, Feng B, Huang SM, Liu X, Smith QR, Zhang LK, Zamek- Gliszczynski MJ (2013) Why clinical modulation of efflux transport at the human blood–brain barrier is unlikely: the ITC evidence-based position. Clin Pharmacol Ther 94 (1):80–94. doi:10.1038/clpt.2013.34
57. Krishna R, St-Louis M, Mayer LD (2000) Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by co-administering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin. Int J Cancer 85(1):131–141
58. Liang XJ, Aszalos A (2006) Multidrug transporters as drug targets. Curr Drug Targets 7(8):911–921
59. Hartz AM, Bauer B, Fricker G, Miller DS (2004) Rapid regulation of P-glycoprotein at the blood–brain barrier by endothelin-1. Mol Pharmacol 66(3):387–394. doi:10.1124/mol.104.001503
60. Hartz AM, Bauer B, Fricker G, Miller DS (2006) Rapid modulation of P-glycoproteinmediated transport at the blood–brain barrier by tumor necrosis factor-alpha and lipopolysaccharide. Mol Pharmacol 69(2):462–470. doi:10.1124/mol.105.017954
61. Cannon RE, Peart JC, Hawkins BT, Campos CR, Miller DS (2012) Targeting blood–brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain. Proc Natl Acad Sci U S A 109(39):15930–15935. doi:10.1073/pnas.1203534109
62. Cartwright TA, Campos CR, Cannon RE, Miller DS (2013) Mrp1 is essential for sphingolipid signaling to p-glycoprotein in mouse blood–brain and blood-spinal cord barriers. J Cereb Blood Flow Metab 33(3):381–388. doi:10.1038/jcbfm.2012.174
63. Kim RH, Takabe K, Milstien S, Spiegel S (2009) Export and functions of sphingosine-1- phosphate. Biochim Biophys Acta 1791(7):692–696. doi:10.1016/j.bbalip.2009.02.011
64. Mitra P, Oskeritzian CA, Payne SG, Beaven MA, Milstien S, Spiegel S (2006) Role of ABCC1 in export of sphingosine-1-phosphate from mast cells. Proc Natl Acad Sci U S A 103 (44):16394–16399. doi:10.1073/pnas.0603734103
65. Hisano Y, Kobayashi N, Kawahara A, Yamaguchi A, Nishi T (2011) The sphingosine 1-phosphate transporter, SPNS2, functions as a transporter of the phosphorylated form of the immunomodulating agent FTY720. J Biol Chem 286(3):1758–1766. doi:10.1074/jbc.M110.171116
66. Kawahara A, Nishi T, Hisano Y, Fukui H, Yamaguchi A, Mochizuki N (2009) The sphingolipid transporter spns2 functions in migration of zebrafish myocardial precursors. Science 323 (5913):524–527. doi:10.1126/science.1167449
67. Fukuhara S, Simmons S, Kawamura S, Inoue A, Orba Y, Tokudome T, Sunden Y, Arai Y, Moriwaki K, Ishida J, Uemura A, Kiyonari H, Abe T, Fukamizu A, Hirashima M, Sawa H, Aoki J, Ishii M, Mochizuki N (2012) The sphingosine-1-phosphate transporter Spns2 expressed on endothelial cells regulates lymphocyte trafficking in mice. J Clin Invest 122 (4):1416–1426. doi:10.1172/JCI60746
68. Greenberg DA, Jin K (2005) From angiogenesis to neuropathology. Nature 438 (7070):954–959
69. Barakat S, Demeule M, Pilorget A, Regina A, Gingras D, Baggetto LG, Beliveau R (2007) Modulation of p-glycoprotein function by caveolin-1 phosphorylation. J Neurochem 101 (1):1–8
70. Barakat S, Turcotte S, Demeule M, Lachambre MP, Regina A, Baggetto LG, Beliveau R (2008) Regulation of brain endothelial cells migration and angiogenesis by P-glycoprotein/ caveolin-1 interaction. Biochem Biophys Res Commun 372(3):440–446
71. Hartz AM, Madole EK, Miller DS, Bauer B (2010) Estrogen receptor beta signaling through phosphatase and tensin homolog/phosphoinositide 3-kinase/Akt/glycogen synthase kinase 3 down-regulates blood–brain barrier breast cancer resistance protein. J Pharmacol Exp Ther 334(2):467–476. doi:10.1124/jpet.110.168930
72. Mahringer A, Fricker G (2010) BCRP at the blood–brain barrier: genomic regulation by 17beta-estradiol. Mol Pharm. doi:10.1021/mp1001729
73. Hartz AM, Mahringer A, Miller DS, Bauer B (2010) 17-beta-Estradiol: a powerful modulator of blood–brain barrier BCRP activity. J Cereb Blood Flow Metab 30(10):1742–1755. doi:10.1038/jcbfm.2010.36
74. Kipp H, Pichetshote N, Arias IM (2001) Transporters on demand: intrahepatic pools of canalicular ATP binding cassette transporters in rat liver. J Biol Chem 276(10):7218–7224
75. Zhong Y, Hennig B, Toborek M (2010) Intact lipid rafts regulate HIV-1 Tat protein-induced activation of the Rho signaling and upregulation of P-glycoprotein in brain endothelial cells. J Cereb Blood Flow Metab 30(3):522–533
76. Storch CH, Ehehalt R, Haefeli WE, Weiss J (2007) Localization of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and modulation of its activity by cholesterol in vitro. J Pharmacol Exp Ther 323(1):257–264. doi:10.1124/jpet.107.122994
77. McCaffrey G, Staatz WD, Sanchez-Covarrubias L, Finch JD, Demarco K, Laracuente ML, Ronaldson PT, Davis TP (2012) P-glycoprotein trafficking at the blood–brain barrier altered by peripheral inflammatory hyperalgesia. J Neurochem 122(5):962–975. doi:10.1111/j.1471-4159.2012.07831.x
78. Campos CR, Schroter C, Wang X, Miller DS (2012) ABC transporter function and regulation at the blood-spinal cord barrier. J Cereb Blood Flow Metab 32(8):1559–1566. doi:10.1038/jcbfm.2012.47
79. Jablonski MR, Jacob DA, Campos C, Miller DS, Maragakis NJ, Pasinelli P, Trotti D (2012) Selective increase of two ABC drug efflux transporters at the blood-spinal cord barrier suggests induced pharmacoresistance in ALS. Neurobiol Dis 47(2):194–200. doi:10.1016/j.nbd.2012.03.040